Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19. These findings are associated with COVID-19 severity and may predict patient survival. The work was published in the journal Nature Biotechnology.
Prior to joining ISB’s faculty, Dr. Wei Wei earned his Ph.D. from Caltech and served as a faculty member at UCLA Medical School. In this Q&A, Wei discusses his research career to date, how research might change over the next decade, and much more.
Dr. Martin Shelton is a post-doctoral fellow in the Hood Lab. Q: What are you currently working on? Our project, which I work on jointly with Rhishikesh Bargaje and Kalliopi Trachana, along with many other great collaborators both within and outside of the ISB, involves measuring the changes that occur within individual cells as populations of those cells transition from one state to another. We use, as a model system,…
3 Bullets: Identifying the most aggressive cells in cancer (cancer stem cells) is essential for designing effective therapy and predicting patient outcomes. Using single-cell analysis techniques, researchers at ISB and Luxembourg Centre for Systems Biomedicine have identified the molecular signatures of two types of malignant breast tissue cells. Researchers found an interesting twist: the two cell types “cooperate” to increase malignancy potential and they promote a third hybrid stem-cell type….
Pictured above: Dr. Qiang Tian, left, and Dr. Edward Lin, right, discuss single-cell analysis technologies developed at Institute for Systems Biology in Seattle. September 22, 2014 – ISB has received a $2.3 million NIH grant over four years in response to NCI’s “Provocative Questions” Initiative. The project will apply ISB’s most advanced single-cell omics technologies to an innovative clinical trial for colorectal cancer (ADAPT). Principal investigator Qiang Tian, MD, PhD,…
